Day: April 2, 2020

AB „Kauno energija“ neeiliniame visuotiniame akcininkų susirinkime, įvykusiame 2020 m. balandžio 2 d., kuriame dalyvavo ir balsavo 3 akcininkai, nuosavybės teise valdantys 42 088 631 vienetų paprastųjų vardinių bendrovės akcijų, kas sudaro 98,33 proc. visų balso teisę turinčių akcijų skaičiaus, nuspręsta:Išrinkti Saulių Lazauską, Justą Limanauską, Rūtą Šimkaitytę-Kudarauskę AB „Kauno energija“ stebėtojų tarybos nariais iki veikiančios stebėtojų tarybos kadencijos pabaigos.Technologijų ir ekonominės analizės skyriaus vyresnioji ekonomistė   Loreta Miliauskienė, tel. (8 37) 305 855

2019 RESULTS AND ACTIVITYOF AGENCE FRANCE LOCALE GROUPUNDERLINE THE ROBUSTNESS AND APPEAL OF ITS MODELFollowing the Supervisory Board meetings of Agence France Locale and the Board Meeting of Agence France Locale – Société Territoriale held on March 26, 2020, which took place under the chairmanship of Jacques Pélissard, AFL Group published its annual report for 2019.The results as of December 31, 2019 confirm that the continued growth of the local authority bank is driven by further expansion in credit activity and a steady pace of new local authority memberships. Gross operating income amounted to -€503 thousand for net banking income of €11,106 thousand.Jacques Pélissard, Chairman of the Board of Directors of Agence France Locale – Société territoriale, and Vice- Chairman of the Supervisory Board of Agence France Locale, underlines...

Copenhagen, Denmark, April 2, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today, as set out in Section 38 in the Danish Capital Markets Act and section 55, cf. 56 of the Danish Companies Act, received the following major shareholder notification from ATP:“ATP has increased its ownership in Bavarian Nordic. Subsequently, ATP holds a total of 11.12% of the share capital and voting rights in Bavarian Nordic A/S.”About Bavarian NordicBavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product...

KØBENHAVN, Danmark, 2. april 2020 – Bavarian Nordic A/S (OMX: BAVA) har i dag, i henhold til §38 i Lov om kapitalmarkeder samt §55 og §56 i Selskabsloven, modtaget følgende storaktionærmeddelelse fra ATP:”ATP har forøget deres ejerandel i Bavarian Nordic A/S. ATP besidder herefter samlet 11,12% af aktiekapitalen og af stemmerne i Bavarian Nordic A/S.”Om Bavarian NordicBavarian Nordic er et fuldt integreret biotekselskab, der er fokuseret på udvikling, produktion og kommercialisering af livsvigtige vacciner. Vi er globalt førende inden for koppevacciner, og er mangeårig leverandør til det amerikanske strategiske nationale beredskabslager af en ikke-replikerende koppevaccine, som er godkendt af de amerikanske sundhedsmyndigheder, også til beskyttelse mod abekopper. Vores kommercielle produktportefølje består endvidere af markedsledende...

Company AnnouncementCopenhagen, 02 April 2020No. 07/2020At the Annual General Meeting of ISS A/S (the “Company”) held today, the annual report for 2019 was adopted with the modification that the Board of Directors had withdrawn the outlook for 2020 as well as its proposal to pay out dividend resulting in the total net profit for 2019 being allocated to retained earnings. In addition, the general meeting decided:to      grant discharge of liability to members of the Board of Directors and the Executive Group Management Board;to      authorise the Board of Directors in the period until 30 April 2021 to approve the Company’s acquisition of treasury shares, on one or more occasions, with a total nominal value of up to 10% of the share capital of the Company, subject to the Company’s holding of treasury shares after such acquisition not exceeding...

NEW YORK, NY, April 02, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — iQSTEL Inc. (OTC: IQST) has completed a shareholder meeting with the original shareholders of Etelix and SwissLink in which both teams are returning a combined 20.8 Million shares.Etelix and SwissLink have seen record growth under the guidance of iQSTEL. Management teams from both companies have long term commitments to iQSTEL and the future with 5G, IoT, domestic and international interconnects along with additional technologies and acquisitions.Mr. Iglesias, the Company’s CEO, commented, “We are very pleased with the significant progress iQSTEL has made over the past few months. As our business plan continues to unfold, teams from both Etelix and SwissLink expressed their belief in iQSTEL’s direction and believe the best course of action is to further facilitate...

Company announcement – No. 14 / 2020Zealand Pharma provides business update related to current COVID-19 situationStrong progress in discovery and clinical pipeline, with positive Phase 2 results and NDA filing for Dasiglucagon HypoPal® Rescue Pen to the U.S. FDA in March Expansion of U.S. commercial infrastructure on-track to be ready for anticipated launch of Dasiglucagon HypoPal® Rescue Pen Secured funding for continued operations with DKK 137 million through a private placement to U.S. institutional investor Zealand Pharma’s Annual General Meeting will be hosted virtually, encouraging shareholders to participate via webcast transmission instead of attending in personCopenhagen, April 2, 2020 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development...

PayPoint PlcAdditional Listing2 April 2020Application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 500,000 ordinary shares of 1/3p each to trade on the London Stock Exchange and to be admitted to the Official List upon issuance. The shares shall rank equally with the existing issued ordinary shares of the Company. It is expected that the admission will commence on 6 April 2020.The shares will be issued and allocated as stated out of the following share scheme:·Share Incentive PlanSarah CarneCompany SecretaryTel: +44 (0) 1707 600 300LEI: 5493004YKWI8U0GDD138

Det ble i dag avholdt ordinær generalforsamling i Wilson ASA.Alle saker ble enstemmig vedtatt som innstilt.Protokoll fra generalforsamlingen følger vedlagt.Wilson ASA Bergen, 2. april 2020Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12VedleggProtokoll generalforsamling 2 april 2020

PayPoint PlcAdditional Listing2 April 2020Application has been made to the UK Listing Authority and the London Stock Exchange for a block listing of 500,000 ordinary shares of 1/3p each to trade on the London Stock Exchange and to be admitted to the Official List upon issuance. The shares shall rank equally with the existing issued ordinary shares of the Company. It is expected that the admission will commence on 6 April 2020.The shares will be issued and allocated as stated out of the following share scheme:·Share Incentive PlanSarah CarneCompany SecretaryTel: +44 (0) 1707 600 300LEI: 5493004YKWI8U0GDD138